Status:
COMPLETED
Readmission Prevention Pilot Trial in Diabetes Patients
Lead Sponsor:
Temple University
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Post-discharge hospital utilization, i.e., readmissions within 30 days of discharge (30d readmissions) and emergency department (ED) visits, are a high-priority quality measure and target for cost red...
Eligibility Criteria
Inclusion
- 1\. Diabetes, defined by pre-admission use of a diabetes-specific medication and/or documentation of the diagnosis in the medical record.
Exclusion
- Age \< 18 years at the time of admission
- Female subjects who are pregnant and/or admitted to an obstetric service
- Current or expected admission to a critical care unit
- Binge drinking (5 or more alcoholic drinks for males or 4 or more alcoholic drinks for females on the same day) or drug abuse within 3 months before admission
- Inpatient death
- Transfer to another hospital or subacute facility
- Discharge to hospice or a long-term care facility
- Discharge expected within 12 hours or admission to a short-stay unit
- Lack of access to a phone
- Living more than 30 miles away from Temple University Hospital (TUH)
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
Key Trial Info
Start Date :
September 7 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2019
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT03243383
Start Date
September 7 2017
End Date
October 1 2019
Last Update
October 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140